FDA gives go-ahead to ST2 biomarker assay
Candace Stuart | December 16, 2011 | Cardiovascular Business | Heart Failure
Critical Diagnostics' Presage ST2 Assay, a cardiac biomarker assay that can be used in the prognosis of patients with chronic heart failure, was cleared by the FDA Dec. 15.

The prognostic tool, which measures soluble ST2 levels in blood, received CE mark in Europe earlier this year.

ST2 is a cardiac biomarker that has been shown to be associated with adverse cardiac remodeling and fibrosis, the company stated. Its presence may indicate MI, ischemia or worsening heart failure.

Candace Stuart, Contributor

Related Content

Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients
Bayer subsidiary granted FDA’s fast track designation for new congestive heart failure treatment
2 out of 5 AFib patients develop heart failure later in life
FDA announces new recall of Abbott’s HeartMate LVADs after 14 deaths
Inter-atrial shunt in RELIEVE-HF improves symptoms in HFrEF, but not HFpEF
Critics call out ‘woefully inadequate’ CMS proposal for inpatient Medicare payments

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup